- Conditions
- Traumatic Brain Injury, Gait Disorders, Neurologic
- Interventions
- HIGT - physical rehab, Low intensity physical therapy
- Other
- Lead sponsor
- Carilion Clinic
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Roanoke, Virginia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1753–1776
of 7,258
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Head and Neck Cancer
- Interventions
- chemotherapy, cisplatin, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 459 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2013
- U.S. locations
- 22
- States / cities
- Tampa, Florida • Atlanta, Georgia • Decatur, Georgia + 17 more
- Conditions
- Preeclampsia, Preeclampsia Postpartum
- Interventions
- Eplerenone
- Drug
- Lead sponsor
- Anna Stanhewicz, PhD
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Thrombocytosis, Myeloproliferative Neoplasms
- Interventions
- Anagrelide CR
- Drug
- Lead sponsor
- Galena Biopharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 11
- States / cities
- Burbank, California • Encinitas, California • Escondido, California + 8 more
- Conditions
- Recurrent Basal Cell Carcinoma
- Interventions
- Patidegib Topical Gel, 2%, Patidegib Topical Gel, Vehicle
- Drug
- Lead sponsor
- Sol-Gel Technologies, Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 14
- States / cities
- Apple Valley, California • Colton, California • Fremont, California + 11 more
- Conditions
- Malignant Glioma
- Interventions
- Enzastaurin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- High Grade Glioma
- Interventions
- 3T MRI
- Other
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IIIA Ovarian Cancer 2014, FIGO Stage IIIA1 Ovarian Cancer, FIGO Stage IIIA2 Ovarian Cancer, FIGO Stage IIIB Ovarian Cancer 2014, FIGO Stage IIIC Ovarian Cancer 2014, FIGO Stage IVA Ovarian Cancer 2014, FIGO Stage IVB Ovarian Cancer 2014, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Stage III Fallopian Tube Cancer AJCC v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
- Interventions
- Carboplatin, Paclitaxel, Ruxolitinib Phosphate, Therapeutic Conventional Surgery
- Drug · Procedure
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 110
- States / cities
- Goodyear, Arizona • Auburn, California • Los Angeles, California + 87 more
- Conditions
- Influenza
- Interventions
- High-Fiber Diet (HFD), Prebiotic Food-Enriched Diet (PreFED)
- Dietary Supplement
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hypertension
- Interventions
- Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1, Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2, Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter, Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1, Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2, Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 11,506 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Major Depressive Disorder
- Interventions
- Ketamine, Placebo
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Sensory Disorders, Autism, Autism Spectrum Disorder, Autism With High Cognitive Abilities, Autistic Behavior, Hyperacusis
- Interventions
- Exposure therapy, Psycho-education, Caregiver education/home program development
- Behavioral
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 2
- States / cities
- Gainesville, Florida
- Conditions
- HPV-related Lower Genital Tract Neoplasias, HPV-related Anal Neoplasias, Early Stage Lower Genital Tract Cancers
- Interventions
- Diagnostic tests for anal cancer screening
- Diagnostic Test
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 35 Years and older · Female only
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 3
- States / cities
- New York, New York • Charleston, South Carolina • Houston, Texas
- Conditions
- Atherosclerosis of Coronary Artery, Cardiovascular Disease, Pulmonary Embolism, Aortic Aneurysm Without Mention of Rupture Nos
- Interventions
- Not listed
- Lead sponsor
- Michael Gallagher
- Other
- Eligibility
- Not listed
- Enrollment
- 334 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Royal Oak, Michigan
- Conditions
- Metastatic Melanoma
- Interventions
- High Dose Interleukin-2, Ipilimumab
- Drug
- Lead sponsor
- Clinigen, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 12
- States / cities
- Tucson, Arizona • La Jolla, California • Miami Beach, Florida + 9 more
- Conditions
- Hyperlipidemia, Dyslipidemia, Hypercholesterolemia
- Interventions
- torcetrapib/atorvastatin, simvastatin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 640 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Alhambra, California + 48 more
- Conditions
- High-Risk Acute Myeloid Leukemia, Treatment-Related Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Interventions
- ALT-803
- Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Hyperlipidemia and Mixed Dyslipidemia
- Interventions
- Evolocumab, Standard of Care
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 3,681 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 107
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 94 more
- Conditions
- Barrett's Esophagus
- Interventions
- CryoBalloon Focal Ablation
- Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Breast Cancer
- Interventions
- acolbifene hydrochloride
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 30 Years to 55 Years · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Prostate Cancer
- Interventions
- high-LET heavy ion therapy, low-LET photon therapy
- Radiation
- Lead sponsor
- Proton Radiation Oncology Group
- Other
- Eligibility
- Male only
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2005
- U.S. locations
- 2
- States / cities
- Loma Linda, California • Boston, Massachusetts
- Conditions
- Breast Cancer
- Interventions
- Self-Report Survey, Qualitative Interviews
- Behavioral
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 25 Years to 85 Years · Female only
- Enrollment
- 265 participants
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Tampa, Florida
- Conditions
- Tumors, Central Nervous System
- Interventions
- Montanide
- Biological
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Lymphopenia, Malignant Glioma
- Interventions
- Laboratory Biomarker Analysis, NT-I7, Placebo
- Other · Biological
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 7 more